Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 827

1.

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.

Buckley HL, Collinson FJ, Ainsworth G, Poad H, Flanagan L, Katona E, Howard HC, Murden G, Banks RE, Brown J, Velikova G, Waddell T, Fife K, Nathan PD, Larkin J, Powles T, Brown SR, Vasudev NS.

BMC Cancer. 2019 Nov 14;19(1):1102. doi: 10.1186/s12885-019-6273-1.

PMID:
31727024
2.

FAIRshake: Toolkit to Evaluate the FAIRness of Research Digital Resources.

Clarke DJB, Wang L, Jones A, Wojciechowicz ML, Torre D, Jagodnik KM, Jenkins SL, McQuilton P, Flamholz Z, Silverstein MC, Schilder BM, Robasky K, Castillo C, Idaszak R, Ahalt SC, Williams J, Schurer S, Cooper DJ, de Miranda Azevedo R, Klenk JA, Haendel MA, Nedzel J, Avillach P, Shimoyama ME, Harris RM, Gamble M, Poten R, Charbonneau AL, Larkin J, Brown CT, Bonazzi VR, Dumontier MJ, Sansone SA, Ma'ayan A.

Cell Syst. 2019 Oct 10. pii: S2405-4712(19)30345-X. doi: 10.1016/j.cels.2019.09.011. [Epub ahead of print]

PMID:
31677972
3.

Aberration-free multi-plane imaging of neural activity from the mammalian brain using a fast-switching liquid crystal spatial light modulator.

Liu R, Ball N, Brockill J, Kuan L, Millman D, White C, Leon A, Williams D, Nishiwaki S, de Vries S, Larkin J, Sullivan D, Slaughterbeck C, Farrell C, Saggau P.

Biomed Opt Express. 2019 Sep 12;10(10):5059-5080. doi: 10.1364/BOE.10.005059. eCollection 2019 Oct 1.

4.

Evidence map of ductal carcinoma in situ management options.

Bouskill K, Hempel S, Richardson A, Ganz PA, Baxi S, Zutshi R, Larkin J, Motala A, Miles JNV, Crandall CJ.

Menopause. 2019 Nov;26(11):1250-1258. doi: 10.1097/GME.0000000000001397.

PMID:
31567868
5.

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD.

N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.

PMID:
31562797
6.

A Postpartum Remote Hypertension Monitoring Protocol Implemented at the Hospital Level.

Hauspurg A, Lemon LS, Quinn BA, Binstock A, Larkin J, Beigi RH, Watson AR, Simhan HN.

Obstet Gynecol. 2019 Oct;134(4):685-691. doi: 10.1097/AOG.0000000000003479.

PMID:
31503166
7.

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.

Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi FS, Kirkwood JM, Kluger HM, Larkin J, Postow MA, Ritchings C, Sznol M, Tarhini AA, Wolchok JD, Atkins MB, McDermott DF.

J Clin Oncol. 2019 Sep 9:JCO1900345. doi: 10.1200/JCO.19.00345. [Epub ahead of print]

PMID:
31498030
8.

The fear and risk of community falls in patients following an intensive care admission: An exploratory cohort study.

Parry SM, Denehy L, Granger CL, McGinley JL, Files DC, Berry MJ, Dhar S, Bakhru RN, Larkin JST, Puthucheary ZA, Clark RA, Morris PE.

Aust Crit Care. 2019 Sep 5. pii: S1036-7314(18)30247-9. doi: 10.1016/j.aucc.2019.04.006. [Epub ahead of print]

PMID:
31495638
9.

Imaging of translocator protein upregulation is selective for pro-inflammatory polarized astrocytes and microglia.

Pannell M, Economopoulos V, Wilson TC, Kersemans V, Isenegger PG, Larkin JR, Smart S, Gilchrist S, Gouverneur V, Sibson NR.

Glia. 2019 Sep 3. doi: 10.1002/glia.23716. [Epub ahead of print]

PMID:
31479168
10.

Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement.

Peach H, Board R, Cook M, Corrie P, Ellis S, Geh J, King P, Laitung G, Larkin J, Marsden J, Middleton M, Moncrieff M, Nathan P, Powell B, Pritchard-Jones R, Rodwell S, Steven N, Lorigan P.

J Plast Reconstr Aesthet Surg. 2019 Jun 28. pii: S1748-6815(19)30299-2. doi: 10.1016/j.bjps.2019.06.020. [Epub ahead of print]

PMID:
31477493
11.

Outcomes following colonic stenting for malignant left-sided bowel obstruction: a systematic review of randomised controlled trials.

Boland PA, Kelly ME, Donlon NE, Rausa E, Beddy DP, McCormick PH, Mehigan BJ, Larkin JO.

Int J Colorectal Dis. 2019 Oct;34(10):1625-1632. doi: 10.1007/s00384-019-03378-z. Epub 2019 Sep 2. Review.

PMID:
31475316
12.

Robust estimation of quantitative perfusion from multi-phase pseudo-continuous arterial spin labeling.

Msayib Y, Craig M, Simard MA, Larkin JR, Shin DD, Liu TT, Sibson NR, Okell TW, Chappell MA.

Magn Reson Med. 2019 Aug 20. doi: 10.1002/mrm.27965. [Epub ahead of print]

PMID:
31429999
13.

Spread tools: a systematic review of components, uptake, and effectiveness of quality improvement toolkits.

Hempel S, O'Hanlon C, Lim YW, Danz M, Larkin J, Rubenstein L.

Implement Sci. 2019 Aug 19;14(1):83. doi: 10.1186/s13012-019-0929-8. Review.

14.

How we treat neurological toxicity from immune checkpoint inhibitors.

Spain L, Tippu Z, Larkin JM, Carr A, Turajlic S.

ESMO Open. 2019 Jul 31;4(Suppl 4):e000540. doi: 10.1136/esmoopen-2019-000540. eCollection 2019. Review.

15.

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.

Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, Dréno B, Yan Y, Wongchenko M, McKenna E, Zhu Q, Mun Y, Hauschild A.

Br J Cancer. 2019 Oct;121(7):522-528. doi: 10.1038/s41416-019-0546-y. Epub 2019 Aug 16.

PMID:
31417188
16.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2019 Aug 13. pii: mdz221. doi: 10.1093/annonc/mdz221. [Epub ahead of print] No abstract available.

PMID:
31406976
17.

Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy.

Masiero M, Li D, Whiteman P, Bentley C, Greig J, Hassanali T, Watts S, Stribbling S, Yates J, Bealing E, Li JL, Chillakuri C, Sheppard D, Serres S, Sarmiento-Soto M, Larkin J, Sibson NR, Handford PA, Harris AL, Banham AH.

Mol Cancer Ther. 2019 Nov;18(11):2030-2042. doi: 10.1158/1535-7163.MCT-18-1176. Epub 2019 Aug 8.

PMID:
31395687
18.

… And Thanks for All the Fish … Medical Journals and Gurus.

Larkin J.

Scott Med J. 2019 Aug;64(3):83-85. doi: 10.1177/0036933019866277. No abstract available.

PMID:
31366297
19.

Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer.

Ingles Garces AH, Au L, Mason R, Thomas J, Larkin J.

Expert Opin Investig Drugs. 2019 Aug;28(8):695-708. doi: 10.1080/13543784.2019.1649657. Epub 2019 Aug 6. Review.

PMID:
31359805
20.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV.

Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22.

PMID:
31345627
21.

Obesity Prevention Interventions and Implications for Energy Balance in the United States and Mexico: A Systematic Review of the Evidence and Meta-Analysis.

Richardson AS, Chen C, Sturm R, Azhar G, Miles J, Larkin J, Motala A, Hempel S.

Obesity (Silver Spring). 2019 Sep;27(9):1390-1403. doi: 10.1002/oby.22540. Epub 2019 Jul 20. Review.

22.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC.

Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17.

PMID:
31221619
23.

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B.

Eur J Cancer. 2019 Jul;116:207-215. doi: 10.1016/j.ejca.2019.05.015. Epub 2019 Jun 15.

PMID:
31212163
24.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C.

Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11.

PMID:
31200321
25.

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib.

Lewis K, Hauschild A, Larkin J, Ribas A, Flaherty KT, McArthur GA, Dréno B, McKenna E, Zhu Q, Mun Y, Ascierto PA.

Eur J Cancer. 2019 Jul;116:45-55. doi: 10.1016/j.ejca.2019.05.002. Epub 2019 Jun 4.

PMID:
31173962
26.

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.

Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR.

Oncologist. 2019 Sep;24(9):1151-e817. doi: 10.1634/theoncologist.2018-0749. Epub 2019 Jun 6.

27.

Activation of the unfolded protein response in high glucose treated endothelial cells is mediated by methylglyoxal.

Irshad Z, Xue M, Ashour A, Larkin JR, Thornalley PJ, Rabbani N.

Sci Rep. 2019 May 27;9(1):7889. doi: 10.1038/s41598-019-44358-1.

28.

To Browse, Click "Search".

Larkin J.

Scott Med J. 2019 May;64(2):41. doi: 10.1177/0036933019848950. No abstract available.

PMID:
31119981
29.

Microfluidic droplet liquid reactors for active pharmaceutical ingredient crystallization by diffusion controlled solvent extraction.

Tona RM, McDonald TAO, Akhavein N, Larkin JD, Lai D.

Lab Chip. 2019 Jun 11;19(12):2127-2137. doi: 10.1039/c9lc00204a.

PMID:
31114833
30.

Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer.

Sharma J, Larkin J 3rd.

Front Pharmacol. 2019 Apr 11;10:324. doi: 10.3389/fphar.2019.00324. eCollection 2019. Review.

31.

An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.

O'Reilly A, Hughes P, Mann J, Lai Z, Teh JJ, Mclean E, Edmonds K, Lingard K, Chauhan D, Lynch J, Au L, Ludlow A, Pattison N, Wiseman T, Turajlic S, Gore M, Larkin J, Husson O.

Support Care Cancer. 2019 May 14. doi: 10.1007/s00520-019-04818-w. [Epub ahead of print]

PMID:
31089820
32.

The Late Effects of Radiation Therapy on Skeletal Muscle Morphology and Progenitor Cell Content are Influenced by Diet-Induced Obesity and Exercise Training in Male Mice.

D'Souza D, Roubos S, Larkin J, Lloyd J, Emmons R, Chen H, De Lisio M.

Sci Rep. 2019 Apr 30;9(1):6691. doi: 10.1038/s41598-019-43204-8.

33.

Current and emerging systemic therapies for cutaneous metastatic melanoma.

Mason R, Au L, Ingles Garces A, Larkin J.

Expert Opin Pharmacother. 2019 Jun;20(9):1135-1152. doi: 10.1080/14656566.2019.1601700. Epub 2019 Apr 26. Review.

PMID:
31025594
34.

Reply to E. Hindié and K.R. Hess.

Long GV, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Hauschild A.

J Clin Oncol. 2019 May 20;37(15):1356-1358. doi: 10.1200/JCO.19.00004. Epub 2019 Apr 2. No abstract available.

PMID:
30939092
35.

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV.

Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27.

PMID:
30928620
36.

Modeling Boronic Acid Based Fluorescent Saccharide Sensors: Computational Investigation of d-Fructose Binding to Dimethylaminomethylphenylboronic Acid.

Kearns FL, Robart C, Kemp MT, Vankayala SL, Chapin BM, Anslyn EV, Woodcock HL, Larkin JD.

J Chem Inf Model. 2019 May 28;59(5):2150-2158. doi: 10.1021/acs.jcim.8b00987. Epub 2019 Apr 22.

PMID:
30908030
37.

Design and methodology of the impact of HemoDiaFIlTration on physical activity and self-reported outcomes: a randomized controlled trial (HDFIT trial) in Brazil.

Pecoits-Filho R, Larkin JW, Poli-de-Figueiredo CE, Cuvello Neto AL, Barra AB, Canhada S, de Campos LG, Woehl J, Gonçalves PB, Han H, de Moraes TP, Raimann JG, Canziani MEF; HDFIT Study Investigators.

BMC Nephrol. 2019 Mar 20;20(1):98. doi: 10.1186/s12882-019-1247-8.

38.

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.

Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dréno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A.

Clin Cancer Res. 2019 Jun 1;25(11):3239-3246. doi: 10.1158/1078-0432.CCR-18-0720. Epub 2019 Mar 1.

PMID:
30824584
39.

Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma.

Hayes AJ, Moskovic E, O'Meara K, Smith HG, Pope RJE, Larkin J, Thomas JM.

Br J Surg. 2019 May;106(6):729-734. doi: 10.1002/bjs.11112. Epub 2019 Feb 28.

40.

Editorial.

Larkin J.

Scott Med J. 2019 Feb;64(1):1. doi: 10.1177/0036933019830890. No abstract available.

PMID:
30782108
41.

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK.

N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.

42.

Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.

Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E, Bahl A, Fife K, Webb A, Crabb SJ, Geldart T, Hill R, Dunlop J, McLaren D, Ackerman C, Wimalasingham A, Beltran L, Nathan P, Powles T.

Eur Urol Focus. 2019 Feb 6. pii: S2405-4569(19)30010-0. doi: 10.1016/j.euf.2019.01.010. [Epub ahead of print]

PMID:
30738795
43.

The Impact of Indigenous Youth Sharing Digital Stories About HIV Activism.

Flicker S, Wilson C; Native Youth Sexual Health Network, Monchalin R, Restoule JP, Mitchell C, Larkin J, Prentice T, Jackson R, Oliver V.

Health Promot Pract. 2019 Feb 6:1524839918822268. doi: 10.1177/1524839918822268. [Epub ahead of print]

PMID:
30724108
44.

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A Jr, Mookerjee B, Schadendorf D.

Eur J Cancer. 2019 Mar;109:61-69. doi: 10.1016/j.ejca.2018.12.015. Epub 2019 Jan 25.

PMID:
30690294
45.

Tumor pH and Protein Concentration Contribute to the Signal of Amide Proton Transfer Magnetic Resonance Imaging.

Ray KJ, Simard MA, Larkin JR, Coates J, Kinchesh P, Smart SC, Higgins GS, Chappell MA, Sibson NR.

Cancer Res. 2019 Apr 1;79(7):1343-1352. doi: 10.1158/0008-5472.CAN-18-2168. Epub 2019 Jan 24.

46.

Colonic stenting as a bridge to surgery in malignant large bowel obstruction: oncological outcomes.

Donlon NE, Kelly ME, Narouz F, McCormick PH, Larkin JO, Mehigan BJ.

Int J Colorectal Dis. 2019 Apr;34(4):613-619. doi: 10.1007/s00384-019-03239-9. Epub 2019 Jan 16.

PMID:
30652215
47.

Preflight Contingency Planning Approach for Fixed Wing UAVs with Engine Failure in the Presence of Winds.

Ayhan B, Kwan C, Budavari B, Larkin J, Gribben D.

Sensors (Basel). 2019 Jan 9;19(2). pii: E227. doi: 10.3390/s19020227.

48.

Longitudinal patterns of health-related quality of life and dialysis modality: a national cohort study.

Eneanya ND, Maddux DW, Reviriego-Mendoza MM, Larkin JW, Usvyat LA, van der Sande FM, Kooman JP, Maddux FW.

BMC Nephrol. 2019 Jan 8;20(1):7. doi: 10.1186/s12882-018-1198-5.

49.

The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study.

Johansson M, Carreras-Torres R, Scelo G, Purdue MP, Mariosa D, Muller DC, Timpson NJ, Haycock PC, Brown KM, Wang Z, Ye Y, Hofmann JN, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Garnier JG, Blanche H, Boland A, Burdette L, Prokhortchouk E, Skryabin KG, Yeager M, Radojevic-Skodric S, Ognjanovic S, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Benhamou S, Cancel-Tassin G, Cussenot O, Weiderpass E, Ljungberg B, Tumkur Sitaram R, Häggström C, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Andreotti G, Beane Freeman LE, Koutros S, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Wilson KM, Gaziano JM, Sesso HD, Freedman ND, Parker AS, Eckel-Passow JE, Huang WY, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, Choueiri TK, Lathrop GM, Deleuze JF, Gunter M, McKay JD, Wu X, Houlston RS, Chanock SJ, Relton C, Richards JB, Martin RM, Davey Smith G, Brennan P.

PLoS Med. 2019 Jan 3;16(1):e1002724. doi: 10.1371/journal.pmed.1002724. eCollection 2019 Jan.

50.

Conservation of Neotropical migratory birds in tropical hardwood and oil palm plantations.

Bennett RE, Leuenberger W, Bosarreyes Leja BB, Sagone Cáceres A, Johnson K, Larkin J.

PLoS One. 2018 Dec 31;13(12):e0210293. doi: 10.1371/journal.pone.0210293. eCollection 2018.

Supplemental Content

Loading ...
Support Center